CoChat

Cell Cycle Machinery:

The DOI matches its Crossref record, with a small difference in title or year; 122 of the 122 references it cites were found in a registry or an index.

Abstract

Loss of normal growth control is a hallmark of cancer. Thus, understanding the mechanisms of tissue-specific, normal growth regulation and the changes that occur during tumorigenesis may provide insights of both diagnostic and therapeutic importance. Control of cell proliferation in the normal mammary gland is steroid hormone (estrogen and progestin)-dependent, involves complex interactions with other hormones, growth factors and cytokines and ultimately converges on activation of three proto-oncogenes (c-Myc, cyclin D1 and cyclin E1) that are rate limiting for the G1 to S phase transition during normal cell cycle progression. Mammary epithelial cell-specific overexpression of these genes induces mammary carcinoma in mice, while cyclin D1 null mice have arrested mammary gland development and are resistant to carcinoma induced by the neu/erbB2 and ras oncogenes. Furthermore, c-Myc, cyclins D1, E1 and E2 are commonly overexpressed in primary breast cancer where elevated expression is often associated with a more aggressive disease phenotype and an adverse patient outcome. This may be due in part to overexpression of these genes conferring resistance to endocrine therapies since in vitro studies provide compelling evidence that overexpression of c-Myc and to a lesser extent cyclin D1 and cyclin E1, attenuate the growth inhibitory effects of SERMS, antiestrogens and progestins in breast cancer cells. Thus, abnormal regulation of the expression of cell cycle molecules, involved in the steroidal control of cell proliferation in the mammary gland, are likely to be directly involved in the development, progression and therapeutic responsiveness of breast cancer. Furthermore, a more detailed understanding of these pathways may identify new targets for therapeutic intervention particularly in endocrine-unresponsive and endocrine-resistant disease.

Overview

Integrity signals

Registry

Crossref · 10.1007/978-0-387-78818-0_12

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 122 references

Cited by

See all 59

Metadata

Authors
Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L.
Affiliations
Garvan Institute of Medical Research (AU)
Corresponding author
Sutherland, Robert L.
Venue
Advances in Experimental Medicine and Biology
Published
2008
Volume
630
Pages
189-205
ISSN
0065-2598 (ISSN-L)
OpenAlex
W94760739
Cited by
59
References
121
Citations by year
2026: 1 · 2025: 2 · 2022: 1 · 2021: 1 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 1 · 2014: 4 · 2013: 5 · 2012: 5
FWCI
24.72
Type
book chapter
Language
en
Open access
closed
Locations
  • Advances in experimental medicine and biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
cell cycle regulation, breast cancer, mammary gland development, c-Myc, cyclin D1, cyclin E1, cyclin E2, steroid hormone signaling, endocrine therapy resistance, tamoxifen resistance, antiestrogens, progestins, proto-oncogenes, G1/S transition, oncogenic Ras
MeSH terms
Breast Neoplasms, Cell Cycle, Humans, Models, Biological, Neoplasms, Hormone-Dependent, Oncogenes, Gene Expression Regulation, Neoplastic, Genes, Tumor Suppressor, Treatment Outcome, Cyclin-Dependent Kinases, Antineoplastic Agents, Hormonal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cell Cycle Machinery:. https://app.cochat.ai/papers/10.1007/978-0-387-78818-0_12
The paper
Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L. (2008). Cell Cycle Machinery:. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-0-387-78818-0_12

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.